Drugs giant Glaxo Wellcome Plc bought the remaining percent of its Japanese joint venture Nippon Glaxo for million pounds million on Thursday in its quest for growth in the world's second biggest market. Analysts in London said they had long expected the buy out of Japanese partner Shin Nihon Jitsugyo Co Ltd, which will also get a . million pounds . billion payout in lieu of the dividend. Nippon Glaxo develops, produces and markets prescription medicines across Japan and has net assets of . billion yen . million , as valued on June . Its post tax profit for the six months to June was . billion yen. After setting up a series of Japanese joint ventures since the early s, Glaxo has moved to take them over in a bid to carve a share in Japan's lucrative marketplace, second only to the U.S. in terms of profitability and sales to the group. Seven percent of Glaxo Wellcome's profits stem from Japan, which represents percent of the world market itself. One London based pharmaceuticals analyst said The deal will be slightly earnings enhancing as it's financed by debt and Japanese interest rates are low at half a percent. The move to take over ventures in Japan would allow the group to accelerate growth plans by launching new products there, including its new respiratory treatments for asthma and the new herpes treatment Valtrex which replaces Zovirax. Another analyst agreed that Japan offered a notable expansion opportunity, saying It's obviously one of the leading growth markets for Glaxo. But shares in Glaxo showed little response, falling a modest . pence to in London. Under the deal, Hiroshi Konishi, president of Nippon Glaxo, and Akira Konishi, vice president and general manager, will give up these positions but remain members of Nippon Glaxo's board, Glaxo Wellcome said. Nippon Glaxo had net assets at June of . billion yen, or million pounds. Its profits after tax for the six months ended June were . billion yen. . Pound . Yen 